L3VLUP
ProSign in

NVS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterNVSJNJ
Q3 202010 holders, $3.8bn30 holders, $26.2bn
Q4 202010 holders, $3.7bn32 holders, $26.6bn
Q1 20219 holders, $3.1bn31 holders, $25.3bn
Q2 202113 holders, $3.8bn37 holders, $25.6bn
Q3 202110 holders, $3.9bn40 holders, $24.1bn
Q4 202114 holders, $4.4bn33 holders, $25.2bn
Q1 202214 holders, $4.4bn35 holders, $28.2bn
Q2 202213 holders, $3.8bn33 holders, $26.9bn
Q3 202213 holders, $3.2bn36 holders, $25.4bn
Q4 202211 holders, $3.9bn35 holders, $27.6bn
Q1 202315 holders, $3.5bn42 holders, $24.5bn
Q2 202311 holders, $3.0bn38 holders, $25.0bn
Q3 202310 holders, $2.9bn37 holders, $18.9bn
Q4 202310 holders, $2.5bn31 holders, $19.0bn
Q1 20249 holders, $2.3bn32 holders, $19.7bn
Q2 20249 holders, $2.5bn35 holders, $20.4bn
Q3 20247 holders, $2.7bn28 holders, $22.3bn
Q4 20248 holders, $2.2bn37 holders, $20.4bn
Q1 20259 holders, $2.6bn32 holders, $20.5bn
Q2 20259 holders, $2.6bn31 holders, $18.4bn
Q3 20257 holders, $2.3bn32 holders, $23.7bn
Q4 20257 holders, $2.0bn29 holders, $27.8bn
Q1 20266 holders, $1.7bn34 holders, $35.6bn
Q2 20269 holders, $999m33 holders, $39.1bn
NVS

Novartis AG

Holders
7
Reported value
$2.7bn
Buyers
3
Sellers
5

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVS (2)

Quantbot Technologies LP, Renaissance Technologies LLC

Only JNJ (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →